benzoxazoles has been researched along with Fatty Liver, Nonalcoholic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 7 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Eguchi, Y; Iida, Y; Iizuka, M; Imajo, K; Loomba, R; Nakajima, A; Nojima, T; Suganami, H; Tamaki, N; Tanigawa, R; Yoneda, M | 1 |
| Abe, H; Goto, R; Kamimura, H; Kamimura, K; Kimura, A; Morita, S; Oda, C; Ohkoshi-Yamada, M; Owaki, T; Sakai, N; Sakamaki, A; Shibata, O; Shinagawa-Kobayashi, Y; Terai, S; Yokoo, T | 1 |
| Asaji, M; Chang, J; Higo, T; Ide, S; Inui, H; Kamada, Y; Kanno, K; Koseki, M; Nishida, M; Ohama, T; Okada, T; Okuzaki, D; Ono, M; Saga, A; Saibara, T; Saito, S; Sakata, Y; Tanaka, K; Yamashita, S; Zhu, Y | 1 |
| Aburatani, H; Anai, M; Asahiyama, M; Fruchart, JC; Fruchart-Najib, J; Kamiya, W; Kodama, T; Matsumura, Y; Murakami, K; Osawa, T; Sakai, J; Sasaki, Y; Takizawa, T; Tanaka, T; Yano, W | 1 |
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
| Aburatani, H; Anai, M; Asahiyama, M; Fruchart, JC; Kamiya, W; Kodama, T; Matsumura, Y; Murakami, K; Osawa, T; Sakai, J; Sasaki, Y; Tanaka, T; Yamamoto, S | 1 |
| Hachisu, Y; Hatanaka, T; Hazama, Y; Kakizaki, S; Kashiwabara, K; Naganuma, A; Nakano, S; Nakano, Y; Saito, N; Tanaka, Y; Tojima, H; Uraoka, T; Yoshida, S; Yoshinaga, T | 1 |
| Fujita, K; Honda, Y; Imajo, K; Kessoku, T; Nagashima, Y; Nakajima, A; Ogawa, Y; Saito, S; Takizawa, T; Tomeno, W; Yoneda, M | 1 |
1 trial(s) available for benzoxazoles and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Topics: Animals; Benzoxazoles; Butyrates; Double-Blind Method; Humans; Liver; Mice; Non-alcoholic Fatty Liver Disease; PPAR alpha | 2021 |
7 other study(ies) available for benzoxazoles and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model.
Topics: Animal Fins; Animals; Animals, Genetically Modified; Benzhydryl Compounds; Benzoxazoles; Butyrates; Diet, High-Fat; Disease Models, Animal; Exome Sequencing; Gene Ontology; Glucosides; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Non-alcoholic Fatty Liver Disease; Oryzias; PPAR alpha; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Sodium-Glucose Transporter 2 Inhibitors; Transcriptome | 2022 |
Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy.
Topics: Animals; Benzoxazoles; Butyrates; Cardiomyopathies; Diet, High-Fat; Dietary Carbohydrates; Disease Models, Animal; Gene Expression; Inflammasomes; Liver; Male; Mice, Inbred C57BL; Myocardium; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease | 2022 |
Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.
Topics: Animals; Benzhydryl Compounds; Benzoxazoles; Butyrates; Carcinoma, Hepatocellular; Glucosides; Liver Neoplasms; Mice; Non-alcoholic Fatty Liver Disease; PPAR alpha; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2022 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |
Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.
Topics: Animals; Benzoxazoles; Butyrates; Disease Models, Animal; Endothelial Cells; Hepatocytes; Humans; Lipid Metabolism; Liver; Macrophages; Mice; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; PPAR alpha; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2020 |
Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study.
Topics: Aged; Benzoxazoles; Butyrates; Humans; Hypertriglyceridemia; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies | 2021 |
Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Topics: Animals; Benzoxazoles; Biomarkers; Biopsy; Butyrates; Disease Models, Animal; Female; Gene Expression Regulation; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rodentia; Severity of Illness Index; Uncoupling Protein 3 | 2017 |